We use both session and persistent Cookies for the purposes set out below: The Company may use Personal Data for the following purposes: We may disclose your personal information in any other way so long as it is with your consent and/or for any other purpose disclosed by Us when You provide the information
Phase 2 results have been published in obesity (Jastreboff and colleagues, N Engl J Med, 2023) and in type 2 diabetes (Rosenstock and colleagues, Lancet, 2023), and the compound has since progressed into the phase 3 TRIUMPH programme
Areas of peer-reviewed scientific inquiry where this compound has appeared
We use cookies to give you a good user experience
Always verify the providers credentials and pharmacy licensing
User further understands and agrees that the Company reserves the right to update, change, alter, or modify its Website, which may cause delay or unavailability